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Abstract
Growing concern about the limited generalizability of trials of preventive interventions has led to
several proposals concerning the design, reporting, and interpretation of such trials. This paper
presents an epidemiologic framework that highlights three key determinants of population impact
of many prevention programs: the proportion of the population at risk who would be candidates
for a generic intervention in routine use, the proportion of those candidates who are actually
intervened on through a specific program, and the reduction in incidence produced by that
program among recipients. It then describes how the design of a prevention trial relates to
estimating these quantities. Implications of the framework include: (1) reach is an attribute of a
program, while external validity is an attribute of a trial, and the two should not be conflated; (2)
specification of a defined target population at risk is essential in the long run and merits greater
emphasis in the planning and interpretation of prevention trials; (3) with due attention to sampling
frame and sampling method, the process of subject recruitment for a trial can yield key
information about quantities that are important for assessing its potential population impact; and
(4) exclusions during subject recruitment can be conceptually separated into intervention-driven,
program-driven, and trial design–driven exclusions, which have quite different implications for
trial interpretation and for estimating population impact of the intervention studied.
Introduction
From a public health standpoint, a preventive intervention aims to minimize the number of
people afflicted by a disease in a defined population. Randomized trials play a key role in
evaluating such interventions because of their potentially high internal validity: avoidance of
bias from unmeasured confounding factors and firmer support for causal inference. Two
roles have been distinguished for randomized trials in this context.1 An efficacy trial seeks to
determine how well the intervention can work under conditions that maximize its chances of
having a favorable impact. An effectiveness trial seeks to determine how well the
intervention does work when implemented through a certain program in real-world
conditions for more broadly representative recipients. Traditionally, efficacy trials come
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first, to be followed by effectiveness trials if the efficacy-trial results are promising.2 This
classification of trial orientations has been extended to add pragmatic implementation or
dissemination trials, which also seek to assess intervention impact on a broad scale.3
Some interventions that have performed well in efficacy trials have yielded disappointing
results when applied more widely.4 Accordingly, several authors have advocated increased
emphasis on external validity (generalizability) in the design, reporting, and interpretation of
trials.5–11 Following this advice is complicated by the fact that many factors can influence
external validity. Rothwell’s review8 listed a diverse set of 39 factors. The RE-AIM
framework has been proposed as a way to conceptualize and measure dissemination
potential by considering Reach, Efficacy, Adoption, Implementation, and Maintenance.5,6,12
An illustration of this framework combined several indicators of each of these five
dimensions into a summary index that was compared between trials on prevention of
diabetes complications.13 RE-AIM’s developers and others9,14 have also proposed new
elements related to external validity for the CONSORT guidelines on trial reporting.15
This paper describes an epidemiologic framework that is intended to clarify concepts and
define key terms involved in evaluating preventive interventions. The framework may offer
a foundation for such efforts as RE-AIM in addressing intervention reach and trial
generalizability, which are sometimes conflated. The framework reinforces the importance
of target-population specification early in trial design. It also distinguishes three kinds of
exclusions in a trial—intervention-driven, program-driven, and trial design–driven—which
affect trial interpretation differently.
Population Impact of a Preventive Intervention
Model components
Consider a scenario that includes:
A health condition to be prevented, such as coronary heart disease, motor vehicle collision
injury, or post-traumatic stress disorder (PTSD) following serious injury.
A defined population at risk for that condition, such as residents of a geopolitical area,
enrollees in an HMO, or patients hospitalized at a certain facility for serious injury and who
could later develop PTSD.
A preventive intervention, such as counseling to aid smoking cessation, low-dose aspirin, or
cognitive behavioral therapy to trauma victims during hospitalization.
A program through which the intervention is implemented, involving a certain quantity and
mix of resources and a certain manner of deploying them.
A candidate for the intervention is defined as a member of the population at risk who would
be considered a suitable intervention recipient in routine practice, not just in a research
context. Candidacy for the intervention may depend on several factors, including:
Disease risk—The intervention may presuppose having a certain attribute associated with
elevated disease risk, such as a high cholesterol level (for coronary heart disease) or being a
victim of intentional injury (for PTSD).
Intervention risk—Some people may have attributes that could increase adverse effects of
the intervention, such as known intolerance to low-dose aspirin.
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Other personal attributes—These may concern whether the intervention could feasibly
be applied to that person, such as having a telephone (for a quit line intervention) or absence
of cognitive impairment (for participation in counseling to prevent PTSD).
Table 1 shows examples of which individuals in a defined population could be regarded as
candidates for different preventive interventions.
Candidacy divides the defined population at risk into two mutually exclusive and
collectively exhaustive subpopulations: candidates and non-candidates. Let:
I = Incidence of health condition in full population at risk
Ic = Incidence among candidates
Inc = Incidence among non-candidates
πc = Proportion of population at risk who are candidates
By a well known relationship among disease-frequency measures [16]:
(1)
In words, overall incidence is a weighted average of incidence among candidates and
incidence among non-candidates. The weights are the population frequency of candidacy
and of non-candidacy, respectively.
Overall impact of an intervention on incidence can be defined under a potential-outcomes
formulation based on the Rubin Causal Model [17–21]. Two hypothetic scenarios are
envisioned here: the intervention is provided to all candidates, or the intervention is not
provided to anyone. Overall incidence is designated I(1) under the first scenario and I(0)
under the second. All other factors are held constant, including time. Actually implementing
such an experiment cannot be done, in part because it is impossible to turn back the clock
and study both scenarios at the same time in the same population. Nonetheless, it is useful
conceptually to define population impact as Δ = I(0) − I(1): that is, the overall reduction in
population incidence caused by the intervention. Various evaluation designs can be viewed
as different ways of estimating Δ indirectly [21]. For example, a randomized trial provides a
direct estimate of I(1) in the experimental group, while incidence in the control group
provides an indirect estimate of I(0). Notation introduced earlier can be extended to
distinguish between the two scenarios. With the intervention:
I(1) = Incidence in full population at risk
Ic(1) = Incidence among candidates
Inc(1) = Incidence among non-candidates
Without the intervention:
I(0) = Incidence in full population at risk
Ic(0) = Incidence among candidates
Inc(0) = Incidence among non-candidates
As before:
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Let Δc = Ic(0) − Ic(1) and Δnc = Inc(0) − Inc(1) denote the difference in incidence between
the with-intervention and without-intervention scenarios among candidates and non-
candidates, respectively. By subtraction:
Interventions applied to candidates can differ in their effects on non-candidates, Δnc. Some
may have “spill-over” effects. For example, vaccination can induce herd immunity, and an
intervention that changes social norms about the acceptability of smoking may affect
smoking behavior even among people not directly targeted. However, for many
interventions, such as low-dose aspirin for heart disease prevention or counseling to prevent
PTSD in trauma victims, it is reasonable to assume that Δnc = 0 (i.e., that intervening on
candidates only has no effect on incidence among non-candidates). When Δnc = 0, then:
(2)
Thus, in the absence of “spill-over” effects, the population impact (Δ) of an intervention
depends on two factors: (1) the reduction in incidence among intervention candidates (Δc)—
a measure of its effectiveness; and (2) the prevalence of candidacy in the population at risk
(πc)—a measure of the intervention’s breadth of applicability.
Factoring the population impact of an intervention into two component parts is reminiscent
of factoring the population attributable fraction (also termed attributable risk) for a certain
exposure into two parts: prevalence of the exposure among disease cases, and attributable
fraction among the exposed, (RR-1)/ RR [22, 23]. Here, however, the relevant prevalence is
that of candidacy for an intervention, and the hypothesized effect of intervention is to reduce
incidence not to the level in non-candidates but to some other level that may be higher or
lower than the incidence among non-candidates.
Population Impact of Two Hypothetic Interventions
Rose24–26 described two prevention strategies: a high-risk strategy, in which intervention is
aimed selectively at those most likely to develop the target condition; and a population
strategy, aiming intervention less selectively at much or all of the population at risk. Figures
1 and 2 concern two hypothetic interventions aimed at preventing PTSD in a certain defined
population at risk: namely, patients hospitalized for trauma. The figures show graphically
how Δc and πc combine to determine the number of cases prevented.
In both scenarios, the defined population at risk consists of 600 hospitalized trauma patients,
150 of whom would develop PTSD in the absence of any intervention. In Figure 1, 100 such
patients are deemed candidates for intervention because they are at high risk for PTSD,
perhaps based on trauma mechanism. Intervention reduces their PTSD risk by 40% from 0.5
to 0.3, as indicated by the dashed line. PTSD risk in non-candidates is 0.2 and is unaffected
by an intervention not directed at them. The area of each shaded rectangle—(width) ×
(height) = (no. of people at risk) × (incidence proportion among them)—is thus proportional
to the number of cases among candidates or among non-candidates in the absence of
intervention, each case being shown as a small circle. Reducing the incidence proportion
among candidates prevents 40% of the 50 cases among candidates, or 20 cases, each shown
as a light circle.
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In Figure 2, a different intervention is applicable to 2/3 of all trauma victims, perhaps those
who speak English. Candidates for this intervention have the same intrinsic risk of PTSD
(0.25) as do non-candidates. Intervention on candidates reduces their PTSD risk 20% from
0.25 to 0.2. As for intervention #1, 20 cases are prevented.
For intervention #1: Δc·πc = (0.5–0.3) ·100/600 = .033. For intervention #2, Δc·πc = (0.25–
0.20)·400/600 = .033. Thus, each intervention would reduce the cumulative incidence of
PTSD in the population as a whole from 0.25 to 0.25 – 0.033 = 0.217. In the current
hypothetic population of 600 people at risk, each intervention would prevent 20 cases of
PTSD, although they would probably not be the same people.
Role of program design
For present purposes, a program is a vehicle through which a generic intervention is actually
delivered. The same generic intervention can be implemented via any of several programs.
The form that a program takes is often heavily influenced by: the nature of the intervention
and program model, which affect level of funding, staff expertise, and time required to
deliver it to each recipient; availability of resources in relation to those requirements; setting
characteristics, including physical, institutional, and cultural environmental factors that
affect what can feasibly be done and at what cost; and possibly interactions among these
factors.6 Programs that implement the same generic intervention can thus differ importantly
as to how they identify potential recipients, how many they can serve, and what eligibility
criteria they apply.
As a result, program recipients may not necessarily be representative of the larger group of
all candidates for the intervention. In particular, program recipients may be skewed as to:
Level of need—Programs may seek out individuals at highest risk for the condition, or
those in whom it would be most severe. For example, when vaccine against H1N1 influenza
was scarce in 2009, many state and local vaccination programs prioritized pregnant women.
Accessibility—Programs may preferentially enroll people who are easiest or less costly to
access, such as those who reside near program headquarters.
Likelihood of intervention impact—Programs may prioritize individuals in whom the
intervention may have its greatest effect, such as those most likely to be compliant.
Ability to pay—Programs that charge recipients for service may preferentially target
people who can cover those costs themselves or through insurance.
Occasionally when demand exceeds supply, a program may use a lottery or the equivalent to
select who receives service. For example, when telephone-call volume to a California
smoking quit line exceeded program capacity, random chance was used to decide which
callers would receive immediate service and which would be advised to call back later.27
These unusual examples are important because they show that sometimes it is possible for
program recipients to be formally representative of a larger program of intervention
candidates.
In the population context, a program’s process of subject enrollment subdivides intervention
candidates into program recipients and non-recipients (Figure 3). As before, overall
incidence of the condition in intervention candidates (Ic) can be expressed as a weighted
average of incidence in program recipients (Ir) and in non-recipients (Inr), where πr|c
denotes the proportion of candidates who receive the program:
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Also following earlier arguments, Ic can be envisioned with the program or without it, and it
can be shown that, in the absence of spill-over effects:
(4)
Lastly, substituting (4) into (2) gives:
(5)
Overall population impact is thus the product of (1) the prevalence of candidacy for the
intervention in the population at risk, (2) the proportion of candidates who receive the
intervention under a particular program, and (3) the amount by which incidence is reduced
among program recipients.
Role of Trial Design
Consider a two-arm, parallel-groups trial comparing a prevention program (experimental
arm) with no program (control arm). Say that nE subjects are randomized to the
experimental arm and nC to the control arm, for a total of n = nE+nC subjects and that the
subscript i = 1… n indexes study subjects. Let E be the set of i-values that identify subjects
in the experimental group and C the set of i-values for subjects in the control group. Lastly,
let  be the true outcome status of subject i, without measurement error.
The potential-outcomes formulation can be used again as the basis for defining the internal
validity of such a trial. Each trial participant has two potential outcomes: Y*(1) if assigned to
the experimental arm and Y*(0) if assigned to the control arm. The average effect of
intervention among subjects who are assigned to the experimental arm would be:
Only  is actually available for measurement, not to mention possible measurement
error. Nonetheless, Δr* is useful conceptually to specify what the trial is designed to
estimate. The observed trial result is:
The first term shows that the experience of the control group serves as the basis for
estimating how the experimental group would have fared if they had instead been subject to
the control condition. The trial’s internal validity can be defined as the degree to which Δr*
= Δr. Comparing expressions for Δr* and Δr reveals two main threats to validity. First,
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outcomes in control-group subjects may not accurately reflect the counterfactual outcomes
of experimental-group subjects had they been assigned instead to the control condition. Any
such discrepancy could reflect selection bias (e.g., corruption of randomization) or chance.
Second, subjects’ observed outcome status may not equal their true outcome status,
reflecting measurement error.
Fundamentally, internal validity concerns whether a trial correctly estimates the effect of an
intervention on the intervention group actually studied. Thus, even a trial that is limited to
highly selected volunteers, who may be further filtered through a complex set of exclusions,
can still have high internal validity.
Assessing a trial’s external validity requires specifying a defined population of trial
nonparticipants and gauging the degree to which trial results (specifically, its estimate of Δr)
would apply to them. Two such defined populations of special interest would be subgroups
of the overall defined population at risk for the target condition: (1) all intervention
candidates; or (2) all individuals who could receive the intervention program under study,
given the trial’s eligibility criteria.
Efficacy trials recruit participants in such a way that it is highly likely that Δr > Δc. To
determine whether the intervention can work under highly favorable circumstances,
participants are chosen as “good” candidates for it. Features of “goodness” may include
being highly compliant, being unlikely to drop out, being unlikely to experience adverse
effects of the program, and so on. If these selection criteria achieve their intended goal, it is
to be expected that program effects seen in efficacy trials would generally exceed the effects
seen if the same intervention approach were applied to all candidates. On the other hand,
efficacy trial participants may be representative of a more restricted subpopulation of
intervention candidates, defined as those who met the efficacy trial’s eligibility criteria. In
terms of equation (5), a higher value of Δr is offset by a lower value of πr|c.
In contrast, effectiveness trials use less restrictive eligibility criteria, such that Δr ≈ Δc more
closely. In some cases, an effectiveness trial can seek to recruit subjects literally at random
from among a defined population of intervention candidates (e.g., the Multicentre Aneurysm
Screening Study trial of early detection and elective repair of abdominal aortic aneurysms in
British men, which recruited subjects from family doctor lists and Health Authority lists
with few exclusions).28
Either a narrowly applied or a broadly applied intervention can be studied with either an
efficacy-trial or an effectiveness-trial orientation. For example, a broad-reach prevention
strategy for heart disease might be low-dose aspirin. Candidates would include almost
everyone, except a few with known intolerance to low-dose aspirin. A narrow-reach strategy
might be statins for adults whose fasting cholesterol exceeds a certain threshold. Candidates
would include only individuals with an elevated fasting cholesterol. Candidates for low-dose
aspirin would almost certainly outnumber candidates for statins.
An efficacy trial of statins would likely recruit highly compliant subjects, perhaps chosen
after a run-in phase, and subjects unlikely to drop out. An effectiveness trial of statins might
draw participants from several primary-care practices, with few exclusions. (Many British
trials involving multiple primary-care practices have this flavor.) An efficacy trial of low-
dose aspirin is exemplified by the Physicians Health Study29: participants were themselves
physicians who demonstrated compliance during a run-in phase. An effectiveness trial of
low-dose aspirin could draw participants from multiple primary-care sites and have much
more inclusive eligibility criteria.
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Frequency and Types of Exclusions during Subject Recruitment
Although the main goal of a prevention trial is typically to estimate Δr, if the trial is viewed
in a population context, the process of recruiting trial participants may yield important
information about πc and πr|c as well. The CONSORT guidelines mandate that trial reports
include a flow diagram that shows how subjects were identified from a larger pool.15
However, the sample flow diagram in the current CONSORT guidelines suggests starting
with “Assessed for eligibility,” then showing how many were excluded due to “Not meeting
inclusion criteria.” The model presented here suggests that it may be of value to
disaggregate “Not meeting inclusion criteria” into separate classes of exclusions that have
quite different implications for interpreting trial results. In particular, three types of
exclusions may be of special interest:
Intervention-driven exclusions disqualify subjects because they would not be candidates for
the generic intervention under any program model, inside or outside the research context.
For example, individuals being screened for a trial of statins would be ineligible under an
intervention-driven exclusion if their fasting cholesterol value was not elevated. The
frequency of intervention-driven exclusions provides information about πc.
Program-driven exclusions disqualify subjects because of features specific to how the
generic intervention was implemented in the program under study, even though these
excluded individuals could be candidates for the generic intervention in routine practice. For
example, subjects who fail a run-in phase might be excluded from participation in a trial of
statins but would still be candidates to receive a statin in regular medical care. The
frequency of program-driven exclusions provides information about πr|c. Excluding a large
number of subjects for program-driven reasons signals an efficacy-trial orientation, which
should raise questions about whether trial results can be safely extrapolated to all candidates
for the generic intervention involved—(i.e., whether Δr ≈ Δc). Excluding only a few subjects
for program-driven reasons signals an effectiveness-trial orientation, under which the Δr ≈
Δc approximation may hold more closely.
Trial design–driven exclusions disqualify subjects for reasons peculiar to requirements of
the research study, even if these individuals would otherwise be eligible to receive the
intervention under the same program model outside the research context. For example,
individuals with a low literacy level that would preclude their completion of a key outcome-
measurement instrument might be excluded from an efficacy trial, even though they would
be part of the program’s target population otherwise.
A separate paper illustrates how a simpler version of this categorization scheme was used to
compare two PTSD prevention programs.30 Admittedly, it may not always be obvious how
to classify a particular exclusion: for example, subject refusal may reflect unwillingness to
receive the intervention under study (an intervention-driven exclusion) or unwillingness to
shoulder the respondent burden posed by a lengthy set of outcome-assessment instruments
(a trial design–driven exclusion). In time, this ambiguity may be lessened by encouraging
trialists to ask follow-up questions about the reasons for refusal. Sensitivity analysis can also
be applied, formally or informally, to gauge the effect of alternative classifications.
Discussion
A contribution of the epidemiologic framework described here is that it may help to put such
commendable efforts as RE-AIM on a firmer footing. Under the framework, the public
health impact of a prevention program can be seen to depend on both the proportion of the
population at risk who are candidates for a certain generic intervention, as well as on the
proportion of candidates who actually receive the intervention via the program. The latter
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(πr|c in the notation used here) corresponds more closely to the concept of reach in the RE-
AIM model.5 But comparing the reach of alternative prevention programs aimed at the same
condition may not be very meaningful if the generic interventions differ. In any case, reach
is an attribute of a program, not of a trial. Generalizability (external validity), in contrast, is
an attribute of a trial, and the two should not be conflated. Moreover, the algebraic
relationships that follow from the framework may help guide development and refinement
of measures of reach and of generalizability. A recent attempt to operationalize the RE-AIM
framework set forth a summary score, defined as the mean of four dimension-specific
subscores, each involving a custom arithmetic combination of several items.13 The authors
suggested that future studies experiment with different ways of combining relevant
information. The present work may be a first step in that direction.
Under this framework, there is no intrinsic competition between the internal and external
validity of a trial. An effectiveness trial may be just as internally valid as an efficacy trial, as
long as it yields a correct estimate of the effect of the intervention under study among trial
participants. Efficacy trials and effectiveness trials aim to estimate the effect of an
intervention on different groups. Neither kind of trial should be faulted for failing to
estimate accurately the effect of intervention on those who would be studied in the other
kind of trial. One corollary is that effectiveness trials can be designed rigorously and should
be held to high standards. Specification of a defined population at risk is a key feature of this
framework. In the current PTSD-prevention examples, a registry of hospitalized trauma
patients could provide a convenient way to identify a defined population.31 Enrollees in a
certain insurance plan may also provide a good starting point. Yet many trials are conducted
on convenience samples of volunteers. Such trials arguably can tell us how well a prevention
program works in some collection of people, but they provide little basis for estimating the
proportion of any defined population that would be candidates for the intervention or be
reached by a certain program that implements it. They can also leave much uncertainty
about how large a reduction in incidence to expect. Longford32 has noted that it is rarely
feasible to enroll trial participants strictly at random from a defined population. Still, some
recruitment strategies approximate that ideal more closely than others. From a public health
viewpoint, the usefulness of results from a trial can be enhanced if the sampling frame and
sampling method for trial participants is described.
Finally, the framework described here focuses attention on exclusions during trial
recruitment. Intervention-driven exclusions can bear on the prevalence of candidacy for the
intervention under study—a key factor in estimating its potential population impact.
Program-driven exclusions can help readers gauge the program’s penetration among
candidates, as well as the degree to which program recipients are likely to be typical of all
intervention candidates. Trial design–driven exclusions can be important to count separately
because, even though they may have limited participation in the study program under
research conditions, they may not limit participation under real-world conditions. These
kinds of exclusions can guide judgments about the degree to which observed program
effects are likely to reflect those to be expected in routine practice. The frequency and nature
of exclusions can thus tell us where a trial fits in the longer arc of evidence development
about a preventive intervention.
All models simplify reality, and that simplification imposes limitations. One possibility has
been ignored: that an intervention may be applied, intentionally or not, to people outside the
working definition of candidacy, as when a drug is used for off-label indications. Figure 3
subdivides a population at risk using only two branch points. A more complex model might
“un-bundle” a set of eligibility criteria to create a more elaborate tree with multiple branch
points (and multiple associated parameters to be estimated). Personal characteristics that
underlie different exclusions may be associated with each other, which may complicate the
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task of estimating the consequences of adding or removing a particular exclusion. Lastly,
difference-in-incidence measures have been used to quantify intervention impact, even
though ratio-of-incidence measures are also often used to report trial results. These two
kinds of measures are easily reconciled if incidence in at least one group is known or
estimable.
These limitations notwithstanding, it is hoped that the epidemiologic framework presented
here will be useful to trial designers, to authors and editors, and to consumers of research
results. It may also help to guide how quantitative assessments of population impact may
influence ratings of “overall impact” when competing grant applications are reviewed for
scientific merit by federal health agencies.
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Hypothetic Intervention #1 to Prevent PTSD in Trauma Victims, Illustrating the “Narrow-
Reach” Strategy
PTSD, post-traumatic stress disorder
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Hypothetic Intervention #2 to Prevent PTSD in Trauma Victims, Illustrating the “Broad-
Reach” Strategy
PTSD, post-traumatic stress disorder
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Formation of Key Subpopulations from an Overall Defined Population at Risk
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Table 1
Examples of candidates for different preventive interventions
Health condition Intervention Candidates
Coronary heart disease Smoking quit line Smokers with a telephone
Coronary heart disease Statins Adults with high serum cholesterol and no known contraindication to statins
Coronary heart disease Low-dose aspirin every other day Adults with no known contraindications to aspirin
Falls in older adults Hip pads Ambulatory older adults
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